Sedivention raises €800,000 in pre-seed funding for novel obesity therapy 

• The medtech start-up is developing a device for a one-time, minimally invasive therapy for obesity.
• Sedivention has secured €800,000 in funding from High-Tech Gründerfonds (HTGF).
• The fresh capital will be used to advance the first preclinical studies and product development.

Munich, 18 November 2024 – The German medical technology start-up Sedivention has received €800,000 in pre-seed funding from HTGF, one of the leading and most active early-stage investors in Germany and Europe. The Straßlach-based company is developing a
medical device that enables a one-time, interventional, and minimally invasive therapy for obesity.

1.5 billion affected by 2030
Obesity and related diseases already cause 3.7 million deaths a year and are growing rapidly around the globe. Recent studies show that the disease will affect 1.5 billion people by 2030. It has many causes: physical inactivity combined with a high-calorie diet, genetic and psychological factors, sleep deprivation and stress. At some point, all obese people suffer from a dysregulation of hunger and satiety. The feedback loop between food intake and satiety no longer works and, as one sufferer put it, there is an ‘obsession with food’. The vagus nerve plays an important role in this dysregulation.

Cost-effective, outpatient therapy with high efficacy
Sedivention is developing a cryocatheter that ablates the gastric branches of the vagus nerve within minutes. The procedure can be performed in an outpatient setting, similar to a gastroscopy, as a one-time, minimally invasive procedure. The new, innovative and cost-effective procedure will also have a positive impact on obesity-related comorbidities such as diabetes and hypertension.

Obesity is not a consequence of lack of discipline, it is a disease in itself. We help people lose weight. Without surgery, without implants, without lifelong medication.”

Dr. Ute Nollert, Founder of Sedivention 

A prototype has already been developed and successfully tested for safety and efficacy. Sedivention will use the capital raised to advance product development and preclinical testing.

We believe in the idea and approach of Sedivention’s novel therapy and are excited to support the company in its next steps.”

Dr. Jan Engels, Investment Manager at HTGF 

About Sedivention 
Sedivention GmbH was founded in 2021 near Munich. A team of experienced engineers and physicians has developed and successfully tested a prototype. The next steps are product development, followed by initial clinical trials. 

Contact
Sedivention GmbH 
Dr. Ute Nollert (Founder) 
info@sedivention.com  
www.sedivention.com 

About HTGF – High-Tech Gründerfonds 
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 750 start-ups and achieved over 180 successful exits.  
Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
For more information, please visit HTGF.de or follow us on LinkedIn.

Media contact
High-Tech Gründerfonds Management GmbH 
Tobias Jacob, Senior Marketing & Communications Manager  
T.: +49 228 – 82300 – 121 
t.jacob@htgf.de